Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
12.57
+0.01 (0.08%)
At close: Aug 1, 2025, 4:00 PM
12.33
-0.24 (-1.91%)
After-hours: Aug 1, 2025, 4:08 PM EDT

Company Description

Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID).

Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates.

The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies that enable the selective modulation of recruited cytotoxic immune cells for various therapeutic applications; and ProTECT, a tumor-specific immune co-stimulation platform.

Its lead product candidate consists of zanidatamab, a novel bispecific antibody that targets human epidermal growth factor receptor 2 HER2 that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.

In addition, the company develops a pipeline of preclinical product candidates. It has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Zymeworks Inc.
Zymeworks logo
CountryUnited States
Founded2003
IPO DateApr 28, 2017
IndustryBiotechnology
SectorHealthcare
Employees286
CEOKenneth Galbraith

Contact Details

Address:
108 Patriot Drive, Suite A
Middletown, Delaware 19709
United States
Phone302 274 8744
Websitezymeworks.com

Stock Details

Ticker SymbolZYME
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001403752
CUSIP Number98985W102
ISIN NumberUS98985Y1082
SIC Code2834

Key Executives

NamePosition
Kenneth H. Galbraith C.A.Chairman of the Board, Chief Executive Officer and President
Leone D. Patterson CPA, M.B.A.Executive Vice President and Chief Business and Financial Officer
Dr. Paul A. Moore Ph.D.Chief Scientific Officer
Mark HollywoodExecutive Vice President and Head of Technical and Manufacturing Operations
Shrinal InamdarDirector of Investor Relations
Daniel Dex J.D., Ph.D.Senior Vice President, Corporate Secretary and General Counsel
Diana PapoveSenior Manager of Corporate Communications
Dr. Lindsey Foulkes B.Sc., Ph.D.Vice President of Corporate Development
Laura O'ConnorVice President of Human Resources and DEI
Dr. Jeffrey Smith M.D.Executive Vice President and Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Feb 14, 2023SC 13G/A[Amend] Statement of acquisition of beneficial ownership by individuals
Feb 6, 2023SC 13G/A[Amend] Statement of acquisition of beneficial ownership by individuals
Oct 24, 202215-12GSecurities registration termination
Oct 21, 20228-KCurrent Report
Oct 19, 20228-KCurrent Report
Oct 18, 20228-KCurrent Report
Oct 13, 2022S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Oct 13, 2022S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Oct 13, 2022S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Oct 13, 2022S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments